14 Results

People

  1. Younes
    Younes
  2. Batlevi
    Batlevi
  3. Brentjens
    Brentjens
  4. Cheung
    Cheung
  5. Escorcia
    Escorcia
  6. Kushner
    Kushner
  7. La Quaglia
    La Quaglia
  8. Ladanyi
    Ladanyi
  9. Landgren
    Landgren
  10. Luo
    Luo

Groups

  1. Center for Hematologic Malignancies (14)
  2. Department of Medicine (12)
  3. Hematologic Malignancies, Division of (12)
  4. Adult Leukemia (5)
  5. GSK Faculty (4)
  6. Hematologic Malignancies Research (4)
  7. Lymphoma (4)
  8. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (3)
  9. Executive Committee, Center for Hematologic Malignancies (3)
  10. Bone Marrow Transplant (2)
  1. "Center for Hematologic Malignancies"
  2. "Future Medicine"
Formats
  1. Journal Article (7)
  2. Review (4)
  3. Book Whole (2)
  4. Book Section (1)
Groups
  1. Center for Hematologic Malignancies (14)
  2. Department of Medicine (12)
  3. Hematologic Malignancies, Division of (12)
  4. Adult Leukemia (5)
  5. GSK Faculty (4)
  6. Hematologic Malignancies Research (4)

More Groups

People
  1. Anas Younes (3)
  2. Anthony Mato (1)
  3. Brian Kushner (1)
  4. Carl Landgren (1)
  5. Carlos Villa (1)
  6. Connie Batlevi (1)

More People

Years
  1. 2023 (1)
  2. 2022 (3)
  3. 2021 (1)
  4. 2019 (1)
  5. 2018 (1)
  6. 2015 (6)

More Years

Publications
  1. Future Oncology (8)
  2. Hodgkin and Non-Hodgkin Lymphomas Seen Through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy (3)
  3. Epigenomics (1)
  4. Immunotherapy (1)
  5. Nanomedicine (1)
Publishers
  1. Future Medicine (14)

Results (14)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Plain language summary of the iNNOVATE study: Ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia
    Review

    Buske, C.; Tedeschi, A.; Trotman, J.; García-Sanz, R.; MacDonald, D.; Leblond, V.; Mahe, B.; Herbaux, C.; Matous, J. V.; Tam, C. S.; more...
    Future Oncology (2023)

    Fulltext@MSK | Save
  • MAJIC: A phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
    Review

    Ryan, C. E.; Davids, M. S.; Hermann, R.; Shahkarami, M.; Biondo, J.; Abhyankar, S.; Alhasani, H.; Sharman, J. P.; Mato, A. R.; Roeker, L. E.
    Future Oncology (2022)

    Fulltext@MSK | Save
  • Phase III MANIFEST-2: Pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
    Review

    Harrison, C. N.; Gupta, V. K.; Gerds, A. T.; Rampal, R.; Verstovsek, S.; Talpaz, M.; Kiladjian, J. J.; Mesa, R.; Kuykendall, A. T.; Vannucchi, A. M.; more...
    Future Oncology (2022)

    Fulltext@MSK | Save
  • Patient preferences for treatment in relapsed/refractory diffuse large B-cell lymphoma: A discrete choice experiment
    Journal Article

    Birch, K.; Snider, J. T.; Chiu, K.; Baumgardner, J.; Wade, S. W.; Shah, G.
    Future Oncology (2022)

    Fulltext@MSK | Save
  • Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies
    Journal Article

    Shah, N.; Perales, M. A.; Turtle, C. J.; Cairo, M. S.; Cowan, A. J.; Saeed, H.; Budde, L. E.; Tan, A.; Lee, Z.; Kai, K.; more...
    Future Oncology (2021)

    Fulltext@MSK | Save
  • Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics
    Review

    Anderson, K. C.; Landgren, O.; Arend, R. C.; Chou, J.; Jacobs, I. A.
    Future Oncology (2019)

    Fulltext@MSK | Save
  • Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia
    Journal Article

    Stein, E. M.
    Future Oncology (2018)

    Fulltext@MSK | Save
  • Hodgkin and non-Hodgkin lymphomas seen through their microenvironment: Impact on diagnosis, prognosis and innovative therapy
    Book Whole


    Future Medicine (2015)

    Fulltext@MSK | Save
  • Hodgkin and non-Hodgkin lymphomas seen through their microenvironment: Impact on diagnosis, prognosis and innovative therapy
    Book Whole


    Future Medicine (2015)

    Fulltext@MSK | Save
  • Hodgkin lymphoma microenvironment: Old and new therapeutic targets
    Book Section

    Batlevi, C. L.; Younes, A.
    In Carbone, A.; Younes, A. (Eds.) Hodgkin and Non-Hodgkin Lymphomas Seen Through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy (2015)

    Fulltext@MSK | Save